Deep Dive
来自我们记者的行业洞察
The rise of China's biotech industry raises industry thresholds, forcing American companies to adjust strategies
The rapid rise of Chinese biotech startups is reshaping the global drug development landscape. American pharmaceutical companies and investment institutions are finding that the number of licensing deals from China has surged, and drug quality has significantly improved, evolving from "me-too" drugs to "me-better" or even first-in-class drugs. Facing geopolitical uncertainties and increasingly fierce competition, American biotech companies must reassess their positioning and focus on truly differentiated innovation.
Endometriosis drug research is chronically underfunded, facing common dilemmas in women's health
Endometriosis affects approximately 10% of women globally, yet related drug research has long been underfunded, facing challenges such as lack of information and inadequate representation in clinical trials. This article examines the challenges and progress in research and development in this field from the perspectives of patients, researchers, and industry professionals.
Biotech startups rely on venture capital, financing dynamics tracking platform launched
Drug development is costly and risky, and biotech startups often rely on venture capital to sustain operations. This database tracks investment rounds from 26 active venture capital firms, revealing industry trends.
10 Clinical Trials Worth Watching in the Second Half of 2024
In the second half of 2024, multiple key clinical trials will see data readouts, covering areas such as obesity, inflammatory bowel disease, schizophrenia, depression, lupus, lung cancer, cardiovascular disease, and cytomegalovirus. The results of these trials may reshape the competitive landscape in related therapeutic areas, affecting the market positions of multiple pharmaceutical companies including Novo Nordisk, Amgen, AbbVie, Bristol Myers Squibb, Biogen, Roche, and Moderna.
Drug patents protect pharmaceutical profits: a guide to patent expiration timelines
The patent system grants pharmaceutical companies legal monopolies to reward their R&D investments and keep generics off the market for extended periods. As the industry faces a 'patent cliff' with over $200 billion in annual revenue at risk from the late 2020s through 2030, companies are confronting critical choices between boosting R&D or filling gaps through acquisitions. Based on 2025 sales figures, BioPharma Dive has compiled the core patent expiration dates for the top 50 best-selling drugs, detailing its data sources and methodology.
New drugs for postpartum depression are on the market, but barriers to diagnosis and treatment remain
Although two drugs specifically targeting postpartum depression (PPD) have been approved and launched in the United States, their clinical application has progressed slowly due to factors such as insufficient social awareness, late establishment of diagnostic criteria, and poor treatment accessibility. This article reviews the history of PPD from being overlooked to gaining formal diagnostic status, analyzes the limitations of existing treatment options, and explores the practical challenges in promoting the new drugs.